Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mouridsen HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM. Bastholt L, et al. Among authors: gjedde sb. J Clin Oncol. 1996 Apr;14(4):1146-55. doi: 10.1200/JCO.1996.14.4.1146. J Clin Oncol. 1996. PMID: 8648369 Clinical Trial.
A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.
Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT. Jakobsen P, et al. Among authors: gjedde sb. Cancer Chemother Pharmacol. 1991;28(6):465-9. doi: 10.1007/BF00685824. Cancer Chemother Pharmacol. 1991. PMID: 1934250 Clinical Trial.
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer.
Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, Larsen SO, Rørth M, Mouridsen H, Dombernowsky P. Pedersen-Bjergaard J, et al. Among authors: gjedde sb. J Clin Oncol. 1992 Sep;10(9):1444-51. doi: 10.1200/JCO.1992.10.9.1444. J Clin Oncol. 1992. PMID: 1517787 Clinical Trial.
Phase II study of tauromustine in disseminated malignant melanoma.
Nolte H, Gjedde SB, Lindegaard-Madsen E, Bergh J, Blomquist E, Mouridsen HT. Nolte H, et al. Among authors: gjedde sb. Eur J Cancer Clin Oncol. 1989 Apr;25(4):655-7. doi: 10.1016/0277-5379(89)90201-0. Eur J Cancer Clin Oncol. 1989. PMID: 2714342
Phase I study of tauromustine administered in a weekly schedule.
Gjedde SB, Mouridsen HT, L-Madsen E, Jensen NV, Blomquist E, Bergh J, Söderberg M, Wählby S. Gjedde SB, et al. Eur J Cancer. 1993;29A(13):1901-2. doi: 10.1016/0959-8049(93)90547-s. Eur J Cancer. 1993. PMID: 8260251 Clinical Trial.
Phase II study of tauromustine in disseminated malignant melanoma.
Gjedde SB, Mouridsen HT, L-Madsen E, Jensen NV, Blomquist E, Bergh J, Söderberg M, Wählby S. Gjedde SB, et al. Eur J Cancer. 1994;30A(4):566. doi: 10.1016/0959-8049(94)90448-0. Eur J Cancer. 1994. PMID: 8018421 Clinical Trial. No abstract available.
32 results